Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

"On behalf of Bako and StrataDx, we are excited about the opportunity to join the Fulgent Genetics family,†said Ted Hull, Bako and StrataDx's CEO. "By joining forces, we will bring together advanced technology, digital capabilities, and specialized expertise to better serve our clients. This collaboration EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent†), a technology-based company with a well-established laboratory services business and a therapeutic development busines ...